8/103 sources · 3 publishersUpdated Oct 8, 17:38 UTC
Arvinas presents Phase 1 oculomotor and biomarker data for ARV‑102 in Parkinson’s patients
Arvinas reported results from a 28‑day Phase 1 study of its oral PROTAC degrader ARV‑102 in 24 Parkinson’s disease patients. Doses ranging from 20 mg to 80 mg produced dose‑dependent improvements in saccadic hypometria and reductions in cerebrospinal fluid LRRK2 protein and other disease‑related biomarkers. The company said the findings support continued clinical evaluation of ARV‑102 for neurodegenerative diseases linked to LRRK2 dysregulation.
Why it matters
Arvinas states the data justify further clinical development of ARV‑102, which could expand its pipeline and affect future revenue potential.
Key facts
- 1The trial lasted 28 days and enrolled 24 patients with Parkinson’s disease. globenewswire.com
- 2Oral doses of ARV‑102 ranged from 20 mg to 80 mg, with a placebo arm. globenewswire.com
- 3Dose‑dependent increases in amplitude of saccadic hypometria were observed versus placebo. globenewswire.com
- 4Reductions in CSF LRRK2 protein levels correlated with improvements in oculomotor function. globenewswire.com
- 5Biomarker changes included decreases in endolysosomal and neuroinflammatory markers and increases in synaptic integrity markers. globenewswire.com
- 6Arvinas said the findings support continued clinical evaluation of ARV‑102. globenewswire.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.